Ad
related to: platinum resistant ovarian cancer incidencegotoper.com has been visited by 10K+ users in the past month
Search results
Results from the WOW.Com Content Network
If ovarian cancer recurs, it is considered partially platinum-sensitive or platinum-resistant, based on the time since the last recurrence treated with platins: partially platinum-sensitive cancers recurred 6–12 months after last treatment, and platinum-resistant cancers have an interval of less than 6 months.
COPENHAGEN, Denmark, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced initial data showing signs of clinical activity in heavily pre-treated patients with platinum-resistant ovarian cancer (PROC) treated with TransCon IL-2 β/γ in combination with chemotherapy in its ongoing Phase 1/2 IL-Believe Trial of ...
Mirvetuximab soravtansine is indicated for the treatment of adults with folate receptor alpha (FRα) positive, platinum-resistant epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. [2] [5] [6] Recipients are selected for therapy based on an FDA ...
As PTX-200, triciribine is currently in a Phase Ib/II study in breast cancer [13]) and a Phase Ib trial in platinum resistant ovarian cancer. [14] These trials completed in 2020 and 2019 respectively without publishing data, suggesting negative results.
In ovarian cancer, the ATP7B gene encodes for a copper efflux transporter, found to be upregulated in cisplatin-resistant cell lines and tumors. Development of antisense deoxynucleotides against ATP7B mRNA and treatment of an ovarian cancer cell line shows that inhibition of ATP7B increases sensitivity of the cells to cisplatin. [39]
PTK7 is expressed by many tumors, including ovarian cancer, breast cancer, and non-small cell lung cancer. [5] Early clinical trial results show a 50% response rate in patients with triple negative breast cancer and an almost complete response in ovarian tumors resistant to platinum-based chemotherapies. [6]
The clinical development of lipoplatin in adenocarcinomas establishes this drug as the most active platinum drug with significantly lower side effects. Preliminary investigations suggest the potential for lipoplatin to be a suitable agent for targeting ovarian cancer in patients with aggressive cisplatin resistance. [7]
Most recently, Genelux announced the publication of positive topline results from its Phase 2 VIRO-15 trial of Olvi-Vec-primed immunochemotherapy in heavily pretreated patients with platinum-resistant or -refractory ovarian cancer (PRROC) in JAMA Oncology. Key Findings of Viro-15 Trial. All patients completed both Olvi-Vec infusions and ...
Ad
related to: platinum resistant ovarian cancer incidencegotoper.com has been visited by 10K+ users in the past month